Bruce Leuchter is the founder of GRIN Therapeutics. GRIN Therapeutics has raised $140M in total funding. Latest round: Series D.
Bruce Leuchter, M.D., is the President and CEO of Neurvati Neurosciences, which operates GRIN Therapeutics. He led GRIN Therapeutics through its Phase 1b Honeycomb study and the initiation of its pivotal Phase 3 Beeline study in Europe. He also announced a strategic partnership and the closing of GRIN Therapeutics' $140 million Series D financing.
Full founder directory · Investor directory · Company funding database · Fundraising library